Search Protocols under revision. Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupImmunodeficienciesDiseasePrimary immunodeficiencySubgroupActivated Phosphoinositide-3-Kinase Delta SyndromeICD10D84.9MeSHPrimary Immunodeficiency DiseasesSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceLeniolisibSupportive substanceLeniolisibSupportive substanceLeniolisibSupportive substanceLeniolisibNo. Substances1Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisksAlopeciaDiarrheaEmetogenicityHeadacheNeutropeniaPyrexiaRashUpper Respiratory Tract Infection only studiesPublicationAuthorRao VKDiseaseAktivierte Phosphoinositid-3-Kinase-Delta-Syndrom, Mutationen PIK3CD oder PIK3R1OriginNational Institutes of Health, Bethesda, MDProtokolle in Überarbeitung 1 protocol foundLeniolisib 70, Activated Phosphoinositide 3-Kinase Delta Syndrome (PID3268 V1.0)
